SHE Center at Dana-Farber and Silverberry Genomix form SHE Biobank, a Population Health Initiative for Research and Education

Dana-Farber and Silverberry Genomix launch the SHE Biobank initiative — a long-term study to investigate the impact of genetic predisposition and environmental exposure to development of disease.

Read more

Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

Read more

Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.

Read more